Your first month on a GLP-1: what to actually expect
Tu primer mes con un GLP-1: qué esperar de verdad
Illustrative image. Does not represent guaranteed results.
In the STEP 1 trial, published in the New England Journal of Medicine with 1,961 adults, the dose-escalation phase lasted 16 weeks before participants reached the full semaglutide dose. Sixteen weeks. Nearly four months.
That matters, because almost everything you will feel — or not feel — during your first month happens while the dose is still climbing. Month one is not the treatment. It is the entrance to it.
Key points
- Dose escalation in the large clinical trials took 16 to 20 weeks before reaching the full dose.
- Nausea and diarrhea were the most common side effects, and in STEP 1 were described as generally mild to moderate and transient.
- In STEP 1, 4.5% of semaglutide participants discontinued because of gastrointestinal events, versus 0.8% on placebo.
- Appetite can drop before the scale moves — those are two different things and they do not happen at the same time.
- Eating very little is not the goal. Losing muscle along with fat is a real risk when protein drops too low.
In this article
Week by week: what is happening in your body
GLP-1s act on appetite signaling and slow how fast the stomach empties. Those two things explain most of the first-weeks experience: you fill up sooner, food stays longer, and hunger between meals drops.
Weeks 1 and 2
Starting dose. Many people notice little. Some notice early fullness or a slightly unsettled stomach. Neither one predicts how things will go later.
Weeks 3 and 4
This is usually when the first dose step-up arrives, and also when digestive symptoms appear or intensify. In the trials, gastrointestinal effects clustered precisely around dose-escalation periods.
What you still will not know
Whether the medication "works" for you. SURMOUNT-1 followed participants for 72 weeks and STEP 1 for 68. One month is roughly 6% of that. Drawing conclusions there is like judging a film by the opening credits.
The side effects, with the real numbers
In STEP 1, nausea and diarrhea were the most common adverse events with semaglutide. The authors described them as typically transient and mild-to-moderate in severity, and noted they subsided over time.
The figure worth keeping in mind is discontinuation: 4.5% of semaglutide participants stopped treatment due to gastrointestinal events, versus 0.8% on placebo. That is a clear minority — but it is not zero, and if it happens to you, the statistic is no comfort.
In SURMOUNT-1 with tirzepatide, discontinuation due to adverse events was 4.3%, 7.1% and 6.2% at the 5, 10 and 15 mg doses, versus 2.6% on placebo. There too, events were mostly gastrointestinal and occurred primarily during escalation.
What actually helps make it manageable
None of this is treatment — these are practical adjustments your clinician will likely mention.
Smaller portions, more often
The stomach empties more slowly. A normal-sized plate feels like double.
Water, seriously
When appetite drops, thirst often goes unnoticed too. And dehydration makes nausea and constipation worse.
Protein first
If you are going to eat less, make what you eat count. This connects directly to our article on protein and muscle during weight loss.
Fried food and alcohol, carefully
These are the two that most often sit badly in the early weeks.
When to call your clinician and not wait
Some things are not "part of the process." Severe, persistent abdominal pain, especially radiating to the back; vomiting that prevents you from keeping fluids down; signs of dehydration. Those get reported, not endured.
The FDA maintains public information on medications containing semaglutide, including warnings and safety reports. It is worth reading at the source.
Who is this NOT for?
If your goal is dropping five pounds for an event in three weeks, this is not the tool. The trials behind these medications ran 68 to 72 weeks.
If you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, these medications are generally not appropriate. Nor during pregnancy or if you are trying to conceive.
If you have prior pancreatitis, gallbladder disease, gastroparesis or kidney disease, this needs a specific conversation with a licensed clinician before starting — not a form.
And if you are not in a position to sustain treatment beyond a few months, read what happens when it stops first. That has been measured, and it is not comfortable.
Frequently asked questions
How long until I see results?
We cannot give you a number or a timeline, and be skeptical of anyone who does. What is published is the trial design: STEP 1 measured at 68 weeks and SURMOUNT-1 at 72. Individual results vary and are not guaranteed.
Is it normal to feel nothing in the first month?
Yes. During the first weeks the dose is still escalating. Many people notice no marked change in that period, and that does not mean treatment will not work.
What if the nausea does not go away?
Talk to your clinician before stopping on your own. In many cases the escalation pace is adjusted. In STEP 1, most gastrointestinal events were transient, but 4.5% did discontinue for that reason.
Can I drink alcohol?
That is a conversation for your clinician. Practically speaking, alcohol is one of the things that sits worst in the early weeks, when the stomach empties more slowly.
Do I still need diet and exercise?
In STEP 1 and SURMOUNT-1 the medication was studied as an adjunct to a lifestyle intervention, not instead of one. The published results reflect that combination.
What is the catch?
That it is not a one-month treatment. The STEP 1 trial extension measured what happens on withdrawal, and one year later participants had regained two-thirds of the weight they lost. You should know that before starting, not after.
Do you offer support in Spanish?
Yes. All of our content and support is available in Spanish.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. — DOI · via PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. — DOI · via PubMed
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. — DOI · via PubMed
- FDA. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. — U.S. Food and Drug Administration
This article is informational and is not medical advice. SCTS1 does not prescribe medication. All medical care, prescriptions, and treatment plans are provided by licensed healthcare providers through our partner platform. Treatment eligibility is determined by a licensed provider. Compounded medications contain the same active ingredient class but are not FDA-approved finished pharmaceuticals. Individual results vary and are not guaranteed.